Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 152.36M | 154.01M | 200.52M | 128.30M | 130.51M | 78.89M |
Gross Profit | 24.63M | 37.28M | 52.78M | 49.03M | 58.86M | 32.57M |
EBITDA | -581.59M | -242.78M | -287.20M | -282.24M | -250.76M | 38.97M |
Net Income | -657.75M | -309.85M | -306.74M | -314.25M | -181.22M | 29.40M |
Balance Sheet | ||||||
Total Assets | 860.79M | 1.26B | 1.75B | 1.77B | 2.01B | 413.98M |
Cash, Cash Equivalents and Short-Term Investments | 343.11M | 389.93M | 631.42M | 772.32M | 1.04B | 318.81M |
Total Debt | 699.11M | 672.43M | 933.93M | 957.37M | 955.36M | 42.00M |
Total Liabilities | 769.15M | 753.85M | 1.04B | 1.20B | 1.22B | 78.49M |
Stockholders Equity | 91.64M | 506.59M | 701.30M | 562.90M | 790.99M | 335.49M |
Cash Flow | ||||||
Free Cash Flow | -183.13M | -212.25M | -268.02M | -280.14M | -117.11M | 18.46M |
Operating Cash Flow | -174.43M | -206.06M | -259.17M | -263.21M | -111.18M | 19.50M |
Investing Cash Flow | 203.37M | 124.00M | 4.60M | 116.08M | -678.53M | -219.32M |
Financing Cash Flow | -47.58M | -42.99M | 108.89M | 9.62M | 1.17B | 251.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $430.64M | ― | -2.91% | ― | -1.86% | -2.01% | |
57 Neutral | $244.79M | ― | -14.51% | ― | 7.71% | -38.97% | |
56 Neutral | $229.87M | ― | -44.97% | ― | 21.06% | -99.70% | |
52 Neutral | $7.45B | 0.30 | -61.93% | 2.28% | 16.62% | 1.04% | |
50 Neutral | $560.22M | ― | -19.79% | ― | 8.60% | -42.76% | |
47 Neutral | $441.12M | ― | -177.29% | ― | -23.99% | -100.40% | |
47 Neutral | $464.90M | ― | -29.16% | ― | 25.77% | 49.44% |
On June 4, 2025, Pacific Biosciences held its Annual Meeting where stockholders approved several key proposals, including the election of four Class III directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, an amendment to the 2020 Equity Incentive Plan was approved, allowing for an increase in the number of shares of the company’s common stock reserved for issuance, which reflects the company’s strategic move to enhance its equity incentive offerings.
The most recent analyst rating on (PACB) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.